Phenotypes and genotypes of high density lipoprotein cholesterol in exceptional longevity

Current Vascular Pharmacology

Volumn 12, Issue 5, 2014, Pages 690-697

  Milman, Sofiya ^a   Atzmon, Gil ^a   Crandall, Jill ^a   Barzilai, Nir ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; APOC3; CETP; Genetics; HDL; Longevity

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN C3; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

AGING; ARTICLE; ASHKENAZI JEW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HEREDITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONGEVITY; MORTALITY; PHENOTYPE; PROTEIN POLYMORPHISM; SURVIVAL; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; GENETICS; PHYSIOLOGY; VERY ELDERLY;

AGED, 80 AND OVER; AGING; ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; GENOTYPE; HUMANS; LONGEVITY; PHENOTYPE;

EID: 84924137819     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111666131219101551     Document Type: Article

References (68)

1. Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, Barzilai N. Clinical phenotype of families with longevity. J Am Geriatr Soc 2004; 52(2): 274-7.
2. Rajpathak SN, Liu Y, Ben-David O, et al. Lifestyle factors of people with exceptional longevity. J Am Geriatr Soc 2011; 59(8): 1509-12.
3. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009; 122(10): 962 e1-8.
4. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65, 229 participants. Arch Intern Med 2010; 170(12): 1024-31.
5. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-81.
6. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290(15): 2030-40.
7. Heijmans BT, Beekman M, Houwing-Duistermaat JJ, et al. Lipoprotein particle profiles mark familial and sporadic human longevity. PLoS Med 2006; 3(12): e495.
8. Baggio G, Donazzan S, Monti D, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998; 12(6): 433-7.
9. Vitale G, Brugts MP, Ogliari G, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) 2012; 4(9): 580-9.
10. Barzilai N, Gabriely I, Gabriely M, Iankowitz N, Sorkin JD. Offspring of centenarians have a favorable lipid profile. J Am Geriatr Soc 2001; 49(1): 76-9.
11. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 1997; 96(1): 37-43.
12. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994; 49(6): M252-7.
13. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet 2007; 370(9602): 1829-39.
14. Wilson PW. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol 1990; 66(6): 7A-10A.
15. Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology 2006; 67(12): 2170-5.
16. Landi F, Russo A, Cesari M, Pahor M, Bernabei R, Onder G. HDLcholesterol and physical performance: results from the ageing and longevity study in the sirente geographic area (ilSIRENTE Study). Age Ageing 2007; 36(5): 514-20.
17. Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F. Geneticepidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp Gerontol 2009; 44(3): 136-60.
18. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466(7307): 707-13.
19. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305(5685): 869-72.
20. Perls T, Kohler IV, Andersen S, et al. Survival of parents and siblings of supercentenarians. J Gerontol A Biol Sci Med Sci 2007; 62(9): 1028-34.
21. Westendorp RG, van Heemst D, Rozing MP, et al. Nonagenarian siblings and their offspring display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden Longevity Study. J Am Geriatr Soc 2009; 57(9): 1634-7.
22. Schoenmaker M, de Craen AJ, de Meijer PH, et al. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur J Hum Genet 2006; 14(1): 79-84.
23. Adams ER, Nolan VG, Andersen SL, Perls TT, Terry DF. Centenarian offspring: start healthier and stay healthier. J Am Geriatr Soc 2008; 56(11): 2089-92.
24. Terry DF, Evans JC, Pencina MJ, et al. Characteristics of Framingham offspring participants with long-lived parents. Arch Intern Med 2007; 167(5): 438-44.
25. Florez H, Ma Y, Crandall JP, et al. Parental longevity and diabetes risk in the Diabetes Prevention Program. J Gerontol A Biol Sci Med Sci 2011; 66(11): 1211-7.
26. Barzilai N, Gabriely I, Atzmon G, Suh Y, Rothenberg D, Bergman A. Genetic studies reveal the role of the endocrine and metabolic systems in aging. J Clin Endocrinol Metab 2010; 95(10): 4493-500.
27. Vergani C, Lucchi T, Caloni M, et al. I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people. Arch Gerontol Geriatr 2006; 43(2): 213-21.
28. Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006; 4(4): e113.
29. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322(5908): 1702-5.
30. Garasto S, Rose G, Derango F, et al. The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects. Ann Hum Genet 2003; 67(Pt 1): 54-62.
31. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 2010; 51(8): 2032-57.
32. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78(5): 1287-95.
33. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002; 13(5): 471-81.
34. Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008; 118(7): 731-42.
35. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102(16): 1886-92.
36. Schechter CB, Barzilai N, Crandall JP, Atzmon G. Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension. Mayo Clin Proc 2010; 85(6): 522-6.
37. Sanders AE, Wang C, Katz M, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 2010; 303(2): 150-8.
38. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011; 22(3): 176-85.
39. Vaarhorst AA, Beekman M, Suchiman EH, et al. Lipid metabolism in long-lived families: the Leiden Longevity Study. Age (Dordr) 2011; 33(2): 219-27.
40. Cellini E, Nacmias B, Olivieri F, et al. Cholesteryl ester transfer protein (CETP) I405V polymorphism and longevity in Italian centenarians. Mech Ageing Dev 2005; 126(6-7): 826-8.
41. Kolovou G, Stamatelatou M, Anagnostopoulou K, et al. Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome. Open Cardiovasc Med J 2010; 4: 14-9.
42. Chen DW, Yang JF, Tang Z, et al. Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE epsilon4 in Chinese. Brain Res 2008; 1187: 52-7.
43. Johnson W, Harris SE, Collins P, Starr JM, Whalley LJ, Deary IJ. No association of CETP genotype with cognitive function or agerelated cognitive change. Neurosci Lett 2007; 420(2): 189-92.
44. Qureischie H, Heun R, Lutjohann D, et al. CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. Brain Res 2008; 1232: 1-6.
45. Yu L, Shulman JM, Chibnik L, et al. The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease. Aging Cell 2012; 11(2): 228-33.
46. Arai Y, Hirose N, Yamamura K, et al. Deficiency of choresteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity. J Mol Med (Berl) 2003; 81(2): 102-9.
47. Pan SL, Wang F, Lu ZP, et al. Cholesteryl ester transfer protein TaqIB polymorphism and its association with serum lipid levels and longevity in Chinese Bama Zhuang population. Lipids Health Dis 2012; 11: 26.
48. Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997; 17(6): 1053-9.
49. Koropatnick TA, Kimbell J, Chen R, et al. A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japaneseamerican men. J Gerontol A Biol Sci Med Sci 2008; 63(11): 1235-40.
50. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299(11): 1265-76.
51. Lescai F, Marchegiani F, Franceschi C. PON1 is a longevity gene: results of a meta-analysis. Ageing Res Rev 2009; 8(4): 277-84.
52. Rea IM, McKeown PP, McMaster D, et al. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol 2004; 39(4): 629-35.
53. Feng J, Zhang J, Liu M, et al. Association of mtDNA haplogroup F with healthy longevity in the female Chuang population, China. Exp Gerontol 2011; 46(12): 987-93.
54. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, Barzilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 2002; 57(11): M712-5.
55. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010; 55(25): 2846-54.
56. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2011; 60(8): 1094-102.
57. Van Hemelrijck M, Garmo H, Holmberg L, et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 2011; 117(10): 2086-95.
58. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380(9841): 572-80.
59. Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001; 103(23): 2828-33.
60. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285(12): 1585-91.
61. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341(6): 410-8.
62. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365(24): 2255-67.
63. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22): 1583-92.
64. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306(19): 2099-109.
65. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363(25): 2406-15.
66. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357(21): 2109-22.
67. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350(15): 1505-15.
68. Davidson MH. HDL and CETP Inhibition: Will This DEFINE the Future? Curr Treat Options Cardiovasc Med 2012; 14(4): 384-90.